Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced on August 10, 2026, that it has entered into new distribution partnerships for its ViroCAP® product. The agreements cover Spain, Portugal, Greece, the Balkan region, Romania, and Saudi Arabia, significantly broadening the company's international footprint. Each partnership is with a separate company and pertains to an individual market, with minimum purchase quantities agreed upon in every contract. Based on these agreements, Viromed anticipates additional sales of at least 3,000 devices per year.
ViroCAP® is a mobile medical device designed for treating skin conditions using cold atmospheric plasma. It is intended for use by hospitals, private practice physicians, and surgically active medical specialists. This technology represents a growing area in medical treatments, offering a non-invasive option for various dermatological conditions.
Uwe Perbandt, Chief Executive Officer of Viromed Medical AG, highlighted the significance of these new partnerships, stating, "With these new distribution partners, we are opening up several attractive markets in Southern and South-Eastern Europe as well as in the Middle East. The strong interest shown by our distribution partners underlines the high demand for our cold plasma technology. The new distribution partnerships are another important step in the implementation of our dynamic growth phase. Partnerships for additional countries are in preparation and are expected to be signed within the next four to six weeks."
This expansion is part of Viromed's broader strategy to strengthen its international distribution network. The company already has numerous distribution and marketing partnerships, including an exclusive distribution agreement with South Korea's UMECO covering ten Asian countries, and a partnership with TriPart TITAN GmbH & Co. KG for the Turkish market. These moves indicate a concerted effort to penetrate diverse geographical regions, from Europe to the Middle East and Asia.
The importance of these agreements lies in Viromed's growth trajectory and the increasing adoption of cold plasma technology in medical settings. By securing distribution in six new markets, the company is poised to tap into the healthcare sectors of these regions, potentially improving patient access to innovative treatments. The expected minimum sales of 3,000 devices annually could generate significant revenue, contributing to the company's financial performance and market position.
For the medical industry, the expansion signifies a growing acceptance of cold plasma as a viable treatment modality. Cold atmospheric plasma has been studied for its antimicrobial properties and wound healing benefits, making it a promising tool in dermatology and surgery. As Viromed extends its reach, more healthcare providers across these regions will have the opportunity to incorporate ViroCAP® into their practices, potentially influencing treatment protocols and patient outcomes.
The company's focus on building a robust distribution network is crucial for its long-term success. By partnering with local entities in each market, Viromed can leverage regional expertise and navigate regulatory landscapes more effectively. This strategy also mitigates risks associated with international expansion, allowing for smoother market entry and operational efficiency.
Looking ahead, Viromed plans to sign additional partnership agreements within the next four to six weeks, indicating that its growth phase is far from over. The company, listed on the stock exchange since October 2022, continues to pursue its goal of advancing cold plasma technology in medicine and realizing the corresponding growth potential. With a customer base already established in the DACH region and beyond, these new partnerships are set to enhance Viromed's global presence and solidify its reputation as a pioneer in the field.
